Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen.
Campone M, Campion L, Roché H, Gouraud W, Charbonnel C, Magrangeas F, Minvielle S, Genève J, Martin AL, Bataille R, Jézéquel P. Campone M, et al. Among authors: gouraud w. Breast Cancer Res Treat. 2008 Jun;109(3):491-501. doi: 10.1007/s10549-007-9673-x. Epub 2007 Jul 21. Breast Cancer Res Treat. 2008. PMID: 17659439
Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome.
Decaux O, Lodé L, Magrangeas F, Charbonnel C, Gouraud W, Jézéquel P, Attal M, Harousseau JL, Moreau P, Bataille R, Campion L, Avet-Loiseau H, Minvielle S; Intergroupe Francophone du Myélome. Decaux O, et al. Among authors: gouraud w. J Clin Oncol. 2008 Oct 10;26(29):4798-805. doi: 10.1200/JCO.2007.13.8545. Epub 2008 Jun 30. J Clin Oncol. 2008. PMID: 18591550
A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial.
Jézéquel P, Campone M, Roché H, Gouraud W, Charbonnel C, Ricolleau G, Magrangeas F, Minvielle S, Genève J, Martin AL, Bataille R, Campion L. Jézéquel P, et al. Among authors: gouraud w. Breast Cancer Res Treat. 2009 Aug;116(3):509-20. doi: 10.1007/s10549-008-0250-8. Epub 2008 Nov 20. Breast Cancer Res Treat. 2009. PMID: 19020972
Validation of UBE2C protein as a prognostic marker in node-positive breast cancer.
Loussouarn D, Campion L, Leclair F, Campone M, Charbonnel C, Ricolleau G, Gouraud W, Bataille R, Jézéquel P. Loussouarn D, et al. Among authors: gouraud w. Br J Cancer. 2009 Jul 7;101(1):166-73. doi: 10.1038/sj.bjc.6605122. Epub 2009 Jun 9. Br J Cancer. 2009. PMID: 19513072 Free PMC article.
Prognostic significance of copy-number alterations in multiple myeloma.
Avet-Loiseau H, Li C, Magrangeas F, Gouraud W, Charbonnel C, Harousseau JL, Attal M, Marit G, Mathiot C, Facon T, Moreau P, Anderson KC, Campion L, Munshi NC, Minvielle S. Avet-Loiseau H, et al. Among authors: gouraud w. J Clin Oncol. 2009 Sep 20;27(27):4585-90. doi: 10.1200/JCO.2008.20.6136. Epub 2009 Aug 17. J Clin Oncol. 2009. PMID: 19687334 Free PMC article.
c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1.
Campone M, Noël B, Couriaud C, Grau M, Guillemin Y, Gautier F, Gouraud W, Charbonnel C, Campion L, Jézéquel P, Braun F, Barré B, Coqueret O, Barillé-Nion S, Juin P. Campone M, et al. Among authors: gouraud w. Mol Cancer. 2011 Sep 7;10:110. doi: 10.1186/1476-4598-10-110. Mol Cancer. 2011. PMID: 21899728 Free PMC article.
25 results